The results suggest Bayer’s elinzanetant may help a broader group of women with vasomotor symptoms, which are associated with ...

Kamilia Smith, MD, FACOG, NCMP, discusses how shared decision-making approaches combined with emerging neurokinin-targeted ...

A new, two-step strategy for making substituted piperidines offers chemists a more efficient way to make these biologically ...

The prescribing information for Veozah (fezolinetant) has been updated to include a boxed warning regarding the risk of ...

The research demonstrated the streamlined synthesis of numerous high-value piperidines used in natural products and pharmaceuticals, including neurokinin receptor antagonists, anticancer agents ...

The research demonstrated the streamlined synthesis of numerous high-value piperidines used in natural products and pharmaceuticals, including neurokinin receptor antagonists, anticancer agents ...

Veozah was approved in 2023. At the time, it was the first non-hormonal prescription option for treating hot flashes. The medication works by blocking neurokinin B, a receptor involved in the brain’s ...

The medication works by blocking neurokinin B, a receptor involved in the brain's regulation of body temperature. Since its approval, the drug's popularity has grown steadily, with nearly 29,000 ...

The medication is not a hormone; fezolinetant binds and blocks activities of the neurokinin 3 receptor, which impacts the brain’s body temperature regulation. The updated prescribing information ...